 |
Dear Strategic Tech Investor member,
Nothing is growing faster than the legal marijuana business. Nothing.
By 2029, the market for legal marijuana will reach $100 billion.
That's 1,308% growth from today.
And besides that fact, there's another reason I first started investigating what has become the fastest-growing business sector in the world.
You see, like millions of other Americans, I suffer from chronic pain. To be precise, I suffer from back pain.
While I'm now happy with my medical regiment, I did look at medical marijuana as a possible solution. That's what led me down this particular "rabbit hole."
And as part of my exploration, I've gotten to meet a lot of inspirational legal marijuana entrepreneurs and activists. But I want to tell you about one in particular.
I'm talking about Dr. Avtar Dhillon, the executive chairman of Emerald Health Therapeutics Inc. In Dr. Dhillon, Emerald has...
- An experienced medical doctor...
- A venture capitalist with a great track record...
- And a savvy biotech-company CEO who took a struggling firm and made his investors peak gains of 1,046%.
I think Dr. Dhillon's movement into this space proves what we've been saying for some time now - cannabis is going mainstream in a big way. Just look at how he became a high-profile "pot doc."
Dr. Dhillon told me during one of our chats that he long held a dim view on the use of marijuana. All that changed after he saw a 2013 CNN documentary titled "Weed." It convinced him that cannabis has clear medical benefits.
"I had a skeptical view until then, that cannabis is likely to be just a recreational product," Dr. Dhillon told me over a round of Diet Pepsi. "But I had never really dived into any medical evidence. Dr. Sanjay Gupta did a great job of aligning the evidence and support for it. He, too, had been a skeptic prior to doing his documentary."
Dhillon's track record gives Emerald a huge advantage over other young cannabis firms. About 20 years ago, Dr. Dhillon moved from the world of family medicine to a career in venture capital.
Then in 2001, he became president and CEO of what is now Inovio Pharmaceuticals Inc. (Nasdaq:INO). When Dr. Dhillon joined that developer of DNA-based immunotherapies targeting cancers and infectious diseases, it was badly in need of restructuring.
He got the firm on the fast track - and made his investors a lot of money. Inovio closed at a low of $2.40 on September 2, 2002. Within two years, the stock hit a closing high of $27.52 - for a 1,046.7% gain.
Now, Dr. Dhillon is a bit unique in the world of legal marijuana - but he's not alone. This industry is chock full of entrepreneurs, researchers, and other innovators with fascinating backstories... and proven track records.
And I plan to introduce you to many of them here at Strategic Tech Investor...
But before we do that, I want to do a little "myth busting."
Not All Pot Stocks Are Penny Stocks
A lot of folks I talk to at Silicon Valley networking events, at dinner parties, at the blues concerts I play at, and elsewhere seem to think that the only way to invest in legal marijuana is through risky micro-cap companies.
That's simply not true.
Now, it's true that penny pot stocks can get you rich.
Just ask my Nova-X Report members. Many of them are sitting on micro- and small-cap pot stock gains of 1.511%... 854%... 771%... and 11 more triple-digit winners.
But penny stocks aren't for every sort of investor. And that's why I've put together this report on three "pot stocks" that just about anyone would be comfortable investing in.
All three offer the extreme growth possibilities of marijuana stocks - and the safety of more traditional investments.
To get it, just click here.
Cheers and good investing,
Michael A. Robinson
Director of Technology and Venture Capital Research, Money Morning
P.S. I'm honored to serve as a board member to the only authority in the cannabis investing space. Their experts have hand-picked four of the best "pot stocks" that they believe are the next monstrous winners. Cannabis is set to explode from $10.8 billion a year, to $100 billion, and quite possibly $1 trillion. So the time to act is now before the big surge. Click here to learn more about claiming your stake in this money migration.
Share Strategic Tech Investor:
   
|
You are receiving this e-mail at, ITS028@gmail.com, as a part of your free subscription to Strategic Tech Investor.
Remove your email from this list: Unsubscribe
To cancel by mail or for any other subscription issues, write us at:
Strategic Tech Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201
North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050
Contact Customer Service
Website: https://strategictechinvestor.com
© 2018 Strategic Tech Investor All Rights Reserved.
Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice.
We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Strategic Tech Investor. 1125 N Charles Street, Baltimore, MD 21201.
| |
没有评论:
发表评论